Trials / Completed
CompletedNCT00044408
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 200 (planned)
- Sponsor
- Chromaderm, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this protocol is to determine if an investigational drug known as LY333531 is effective in treating nerve malfunction in diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ruboxistaurin mesylate |
Timeline
- Start date
- 2002-07-01
- Completion
- 2005-10-01
- First posted
- 2002-08-30
- Last updated
- 2016-07-26
Locations
35 sites across 8 countries: United States, Canada, Croatia, Finland, India, Lithuania, Netherlands, United Kingdom
Source: ClinicalTrials.gov record NCT00044408. Inclusion in this directory is not an endorsement.